Skip to main content
Article
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group
Neuro-oncology (2019)
  • Raymond Y. Huang, Brigham and Women's Hospital
  • Wenya Linda Bi, Brigham and Women's Hospital
  • Michael Weller, University of Zurich
  • Thomas Kaley, Memorial Sloan Kettering Cancer Center
  • Jaishri Blakeley, Johns Hopkins University
  • Ian Dunn, Brigham and Women's Hospital
  • Evanthia Galanis, Mayo Clinic
  • Matthias Preusser, Vienna General Hospital
  • Michael McDermott, University of California, San Francisco
  • Leland Rogers, Barrow Neurological Institute
  • Jeffrey Raizer, Medical Neuro-Oncology, Northwestern Medicine, Chicago, Illinois, USA
  • David Schiff, University of Virginia
  • Riccardo Soffietti, University of Turin
  • Jörg Christian Tonn, Ludwig Maximilian University of Munich
  • Michael Vogelbaum, Cleveland Clinic
  • Damien Weber, Paul Scherrer Institut, Villigen, Switzerland
  • David A. Reardon, Brigham and Women's Hospital
  • Patrick Y. Wen, Brigham and Women's Hospital
Publication Date
January 1, 2019
DOI
10.1093/NEUONC/NOY137
Citation Information
Raymond Y. Huang, Wenya Linda Bi, Michael Weller, Thomas Kaley, et al.. "Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group" Neuro-oncology Vol. 21 Iss. 1 (2019) p. 26 - 36
Available at: http://works.bepress.com/michael-mcdermott/304/